


# PRODUCT INFORMATION



## Olsalazine (sodium salt)

Item No. 23661

**CAS Registry No.:** 6054-98-4  
**Formal Name:** 3,3'-(1,2-diazenediyl)bis[6-hydroxybenzoic acid, disodium salt  
**Synonym:** C.I. 14130  
**MF:** C<sub>14</sub>H<sub>8</sub>N<sub>2</sub>O<sub>6</sub> • 2Na  
**FW:** 346.2  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 219, 253, 362 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Olsalazine (sodium salt) is supplied as a crystalline solid. Aqueous solutions of olsalazine (sodium salt) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of olsalazine (sodium salt) in PBS (pH 7.2) is approximately 2 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Olsalazine is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA; Item No. 70265) that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.<sup>1</sup> *In vitro*, olsalazine increases ion transport in isolated rabbit distal ileum when applied to the luminal side (ED<sub>50</sub> = 0.3 mM) and stimulates fluid transport in rat jejunum when used at a concentration of 5 mM.<sup>2,3</sup> Olsalazine (150 mg/kg for 8 days) improves stool consistency and decreases occult and gross bleeding as well as myeloperoxidase (MPO) activity and leukotriene B<sub>4</sub> (LTB<sub>4</sub>; Item No. 20110) levels in colon tissue in a mouse model of acute colitis induced by dextran sulfate (Item No. 23250).<sup>5</sup> Olsalazine also inhibits bovine xanthine oxidase *in vitro* (IC<sub>50</sub> = 3.4 mg/L) and lowers serum uric acid levels in a mouse model of hyperuricemia induced by oxonic acid (Item No. 22586) when administered at a dose of 20 mg/kg.<sup>5</sup> Formulations containing olsalazine have been used in the treatment of inflammatory bowel disease (IBD) and ulcerative colitis.

### References

1. Nugent, S.G., Kumar, D., Rampton, D.S., *et al.* *Gut* **48**(4), 571-577 (2001).
2. Pamukcu, R., Hanauer, S.B., and Chang, E.B. *Gastroenterology* **95**(4), 975-981 (1988).
3. Mohsen, A.Q.M., Mulvey, D., Priddle, J.D., *et al.* *Gut* **28**(3), 346-352 (1987).
4. Murthy, S., Murthy, N.S., Coppola, D., *et al.* *Inflamm. Res.* **46**(6), 224-233 (1997).
5. Niu, Y., Li, H., Gao, L., *et al.* *J. Pharmacol. Sci.* **135**(3), 114-120 (2017).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 • USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)